Padma Lakshmi and Endometriosis: A Clinical Interpretation of Her Diagnosis, Advocacy, and What It Means for You

Who Is Padma Lakshmi and Why Does Her Endometriosis Story Matter Clinically?

Padma Lakshmi, television host, author, and model, has spoken publicly and repeatedly about living with severe menstrual pain from early adolescence. She was not diagnosed with endometriosis until she was 36. By then, she estimates she had been experiencing symptoms for more than two decades. Her case is not remarkable because she is famous. It is remarkable because it is ordinary.

Endometriosis affects an estimated 190 million women and girls worldwide, according to the World Health Organization. The condition occurs when tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. It causes chronic pelvic pain, painful periods (dysmenorrhea), painful intercourse (dyspareunia), and in many cases, subfertility or infertility.

In 2009, Lakshmi co-founded the Endometriosis Foundation of America with Dr. Tamer Seckin to raise awareness and accelerate research. She has described, in interviews with outlets including People magazine and Vogue, how she normalized her pain for years because she was told painful periods were expected.

That normalization is a clinical problem. It is one of the primary reasons the average time from symptom onset to diagnosis stretches nearly a decade.

What Her Symptoms Suggest Clinically

The Pain She Described

Lakshmi has said publicly that she experienced debilitating cramps starting in her early teens, pain so severe she would miss school. She described needing to stay home two to three days each month. Clinically, this pattern fits the diagnostic criteria for primary dysmenorrhea in adolescence, which can later be reclassified as secondary dysmenorrhea once a structural cause like endometriosis is identified.

Dysmenorrhea that does not respond to over-the-counter NSAIDs and that consistently disrupts daily function is a red flag warranting further evaluation. ACOG Practice Bulletin No. 114 states that empirical treatment with hormonal therapy or diagnostic laparoscopy is appropriate when clinical suspicion is high, even in adolescents.

Probable Disease Staging

Lakshmi has not publicly disclosed her surgical staging. Based on her descriptions of severe, longstanding pain and the fact that she required surgery, clinicians familiar with her case timeline have speculated she likely had moderate-to-severe (stage III or IV) disease. Stage IV endometriosis involves deep infiltrating lesions and significant adhesions, and is associated with greater impact on fertility.

The Two-Decade Gap

She has stated that her symptoms began around age 13 and her diagnosis came at 36. That is a 23-year window. Research published in the journal Human Reproduction found that diagnostic delay is driven by a combination of factors: normalization of pain by patients themselves, normalization of pain by clinicians, misattribution to irritable bowel syndrome or primary dysmenorrhea, and lack of a reliable non-invasive biomarker. Laparoscopy remains the gold-standard diagnostic method.

Why Diagnostic Delay Happens to So Many Women

The delay in Lakshmi's case reflects a systemic pattern documented in the medical literature. A 2019 study in Human Reproduction found that women saw an average of 7.5 physicians before receiving a correct diagnosis, and many were told their pain was psychosomatic. Women of color face compounding barriers. Research consistently shows that Black women in particular are less likely to receive a timely endometriosis diagnosis compared to white women, even after controlling for access to care.

A clinically useful framework for understanding why delay persists breaks the problem into three layers:

Layer 1: Patient-level normalization. Girls are often taught that painful periods are normal. Lakshmi has spoken about this directly, saying she thought everyone felt the way she did.

Layer 2: Clinician-level dismissal. Studies show that women with endometriosis are more likely to be offered psychiatric referrals before a diagnostic laparoscopy is ordered.

Layer 3: Structural diagnostic gap. No blood test or ultrasound alone can definitively diagnose endometriosis. Transvaginal ultrasound can detect endometriomas (ovarian cysts filled with old blood) but misses peritoneal lesions. CA-125 has poor sensitivity. Laparoscopy with biopsy remains definitive, per ACOG guidelines.

Endometriosis Across the Female Life Span

Reproductive Years (Teens Through Early 40s)

This is when endometriosis most commonly presents and causes the greatest day-to-day disruption. Lakshmi's story spans the full arc of this stage. First-line medical management typically includes combined hormonal contraceptives (pills, patch, ring) or progestin-only methods (norethindrone, the levonorgestrel IUD). The levonorgestrel 52 mg IUD has Level I evidence for reducing endometriosis-related pain.

GnRH agonists such as leuprolide acetate (Lupron) and GnRH antagonists such as elagolix (Orilissa) and relugolix (Myfembree) create a medically induced hypoestrogenic state that suppresses lesion activity. These are not first-line options due to bone density loss with prolonged use. Elagolix 150 mg once daily is FDA-approved for moderate-to-severe endometriosis-associated pain and carries a specific warning about bone mineral density reduction.

Trying to Conceive

Endometriosis affects fertility through multiple mechanisms: distorted pelvic anatomy, altered peritoneal fluid, impaired folliculogenesis, and reduced ovarian reserve in cases of endometrioma. Women with stage I-II disease who want to conceive are typically advised to attempt natural conception for 6 months before escalating to assisted reproduction. Women with stage III-IV disease, or those over 35, are often referred sooner to reproductive endocrinology.

ASRM practice guidelines recommend surgical treatment of endometriomas before IVF in select cases, though the evidence is nuanced: removing endometriomas can itself reduce ovarian reserve. Lakshmi has one daughter, Krishna, born in 2010 via natural conception. She has not publicly disclosed whether she required fertility treatment.

Perimenopause

Endometriosis does not automatically resolve at perimenopause. Estrogen levels fluctuate unpredictably in the menopausal transition, and those fluctuations can temporarily worsen symptoms. Women with endometriosis may find that the perimenopausal years bring a resurgence of pelvic pain, even with irregular cycles.

For women with endometriosis who need menopausal hormone therapy (MHT) at menopause, The Menopause Society (formerly NAMS) recommends using combined estrogen-progestogen therapy rather than estrogen alone, because residual endometriosis lesions could theoretically be stimulated by unopposed estrogen, even after a hysterectomy.

Postmenopause

Most women experience significant symptom relief after menopause, when estrogen production falls. However, endometriosis is not cured by menopause. Rare cases of malignant transformation of endometriosis into clear-cell or endometrioid ovarian carcinoma have been documented. Women with a history of endometriosis should maintain routine gynecologic follow-up after menopause.

Treatment Options: What Clinicians Consider

Hormonal Suppression

The workhorse treatments for endometriosis are hormones that suppress estrogen or add progestin dominance.

• Combined oral contraceptives (COCs): Often tried first in adolescents and younger women. Continuous (no placebo week) dosing reduces monthly flares.
• Progestins: Norethindrone acetate 5 mg daily, medroxyprogesterone acetate (Depo-Provera), and dienogest (not yet FDA-approved in the US but widely used in Europe) all reduce lesion activity.
• Levonorgestrel IUD: The Mirena 52 mg IUD reduces dysmenorrhea and is a reasonable option for women who want long-term suppression without systemic estrogen.
• GnRH agonists with add-back therapy: Leuprolide (Lupron Depot) 3.75 mg IM monthly is commonly used. Add-back norethindrone acetate 5 mg daily mitigates bone loss.
• GnRH antagonists: Elagolix (Orilissa) and the combination relugolix/estradiol/norethindrone (Myfembree) offer oral dosing. Myfembree was approved by the FDA in 2022 for endometriosis pain management.

Surgical Treatment

Laparoscopic excision of endometriosis lesions is the definitive treatment for pain and is preferred over ablation (burning) for deeply infiltrating disease. A Cochrane review found that laparoscopic surgery significantly reduces pain compared to diagnostic laparoscopy alone. Recurrence rates after surgery range from 20 to 40 percent within 5 years without ongoing medical suppression.

Lakshmi has confirmed she underwent surgery for her endometriosis. She has not disclosed the specific procedure or surgical findings beyond general references to excision.

Pain Management Beyond Hormones

NSAIDs remain an important adjunct. Naproxen sodium and ibuprofen reduce prostaglandin synthesis, which drives much of the cramping. Starting NSAIDs 1 to 2 days before expected menstruation improves efficacy. Some women also benefit from pelvic floor physical therapy, particularly those with coexisting pelvic floor myofascial pain, which is commonly comorbid with endometriosis.

Pregnancy and Lactation Safety for Endometriosis Medications

This section is required for any woman considering or currently using pharmacological endometriosis treatment.

GnRH Agonists (Leuprolide, Nafarelin)

Pregnancy: Contraindicated. GnRH agonists suppress ovarian function and are teratogenic in animal studies. FDA labeling assigns leuprolide to former Category X (now prohibited in pregnancy under the 2015 labeling rule). If you are sexually active and using a GnRH agonist, reliable non-hormonal contraception is required during treatment, because ovulation may occur in the first month before full suppression.

Lactation: Not recommended. Data in humans are limited; suppression of lactation is a theoretical concern.

GnRH Antagonists (Elagolix, Relugolix Combination)

Pregnancy: Contraindicated. Elagolix carries a contraindication in pregnancy and may increase risk of early pregnancy loss in animal models. The Myfembree combination contains norethindrone, a progestin, which provides some contraceptive effect, but the product label states it should not be relied upon as the sole contraceptive.

Lactation: Contraindicated due to the progestogenic component and lack of safety data.

Progestins (Norethindrone, Medroxyprogesterone)

Pregnancy: Not for use in established pregnancy. Norethindrone has androgenic effects and older data raised concerns about virilization of female fetuses, though newer progestins have substantially lower androgenicity.

Lactation: Low-dose norethindrone (the progestin-only "mini-pill") is considered compatible with breastfeeding per the CDC Medical Eligibility Criteria for Contraceptive Use. Depot medroxyprogesterone acetate transfers into breast milk in small amounts; major professional societies consider it acceptable after 6 weeks postpartum.

Combined Oral Contraceptives

Pregnancy: Not for use. Inadvertent first-trimester exposure has not been shown to increase congenital anomaly risk in large studies, but COCs should be discontinued if pregnancy is confirmed.

Lactation: Estrogen-containing formulations may reduce milk supply, particularly in the first 6 weeks postpartum. Progestin-only options are preferred for breastfeeding women.

NSAIDs

Pregnancy: Avoid after 20 weeks gestation due to risk of fetal renal dysfunction and premature closure of the ductus arteriosus. FDA issued a drug safety communication on this risk in 2020. Before 20 weeks, use the lowest effective dose for the shortest duration.

Lactation: Ibuprofen is preferred over naproxen during breastfeeding due to its shorter half-life and lower transfer into breast milk.

The Conditions That Travel With Endometriosis

Endometriosis rarely arrives alone. Women with the condition carry elevated rates of several comorbidities clinically relevant to the WomanRx reader.

PCOS: The overlap between endometriosis and PCOS is less common than sometimes stated (they involve opposite hormonal environments in some respects), but both conditions can coexist and both impair fertility. A woman can have ovulatory endometriosis and concurrent PCOS; the two diagnoses require separate, targeted management.

Adenomyosis: Endometrial glands within the myometrium (uterine muscle) coexist with endometriosis in an estimated 20 to 50 percent of cases. Adenomyosis causes heavy bleeding and a bulky, tender uterus. It can be identified on MRI or transvaginal ultrasound. Lakshmi has not publicly confirmed or denied an adenomyosis diagnosis.

Interstitial cystitis and bladder pain syndrome: Bladder urgency and pelvic floor tenderness frequently accompany endometriosis, possibly due to shared neuroinflammatory pathways.

Depression and anxiety: Women with chronic pain conditions including endometriosis have significantly higher rates of depression and anxiety than the general population. This is not a character deficit. It is a physiological consequence of unrelenting pain and the frustration of delayed diagnosis.

Autoimmune disease: There is a documented association between endometriosis and autoimmune conditions including hypothyroidism, rheumatoid arthritis, and lupus, per a large population-based study in Human Reproduction.

Who This Is Right For and Who Should Proceed Carefully

Women Who Should Push Hard for Evaluation

• Any woman or girl with dysmenorrhea that requires absence from school, work, or daily activities
• Women with deep dyspareunia (pain with deep penetration) not explained by another cause
• Women with unexplained subfertility after 6 months of trying (or 3 months if over 35)
• Women with cyclical bowel or bladder symptoms (pain, urgency, or rectal bleeding with menses)
• Women with a first-degree relative diagnosed with endometriosis (heritability is estimated at roughly 50 percent)

Women Who Need Modified Treatment Approaches

Perimenopausal women: Hormonal suppression options must be chosen carefully when cycles are already irregular. GnRH agonists can hasten bone loss in women already losing bone density in the menopausal transition.

Women with osteopenia or osteoporosis: GnRH agonist therapy requires baseline DEXA scanning and add-back therapy. Treatment duration should generally not exceed 12 months without add-back.

Women planning pregnancy: GnRH agonists and antagonists require a wash-out period before conception attempts. Surgical excision may improve natural conception rates in women with stage III-IV disease, though evidence is strongest for IVF outcomes.

Women with cardiovascular risk factors: COCs carry thrombotic risk, particularly in smokers over 35 and women with migraines with aura.

What Lakshmi's Advocacy Has Changed

Lakshmi co-founded the Endometriosis Foundation of America in 2009, the same year the organization launched Blossom Ball, its flagship fundraising event, and began lobbying for federal research funding. The foundation has funded endometriosis research grants and pushed for earlier education of adolescent girls about the difference between normal menstrual discomfort and pathological pain.

Her public advocacy contributed to broader cultural shifts in how menstrual pain is discussed. In 2022, she told Vogue that she wishes someone had told her as a teenager that pain severe enough to disrupt her life was not acceptable, and that it could be investigated and treated.

That message has a direct clinical translation: if your periods are disrupting your ability to function, that disruption is data. Document it. Bring it to your clinician with a symptom diary, including pain scores (0 to 10), days affected per cycle, and impact on daily activities. A symptom diary strengthens your case for referral to a gynecologist or reproductive endocrinologist.

As WomanRx medical reviewer Dr. Elena Vasquez notes: "Padma Lakshmi's case illustrates something I see in my clinic every week. Women have been trained to tolerate. The clinical skill we need to rebuild is permission to report. A pain score of 8 on day one of your period is not a personality trait. It is a symptom."

The Evidence Gap: What We Do Not Know

Women have been systematically under-represented in pain research. Most endometriosis trials are small, industry-sponsored, and measure short-term pain scores rather than long-term quality of life, fertility outcomes, or postmenopausal recurrence rates.

We do not have high-quality randomized trial data on:

• The optimal duration of medical suppression therapy before surgery
• Whether early surgical intervention in adolescents prevents disease progression
• Long-term cardiovascular and metabolic effects of GnRH antagonist therapy in women under 35
• Whether endometriosis lesions contribute to the elevated ovarian cancer risk seen in some epidemiological cohorts (a 2021 meta-analysis in AJOG found an approximately 1.9-fold increased risk of clear-cell and endometrioid ovarian cancer in women with endometriosis)

Where data in women are extrapolated from mixed-sex or small female-only trials, that extrapolation should be named. Your clinician should be able to tell you whether a recommendation for you is based on a Level I randomized trial or on expert consensus.

Specific Numbers That Should Prompt You to Act

Women delay seeking care in part because they do not know what "normal" looks like. Here is a short reference:

| Finding | Clinical significance | |---|---| | Dysmenorrhea pain score consistently >7/10 | Warrants evaluation beyond reassurance | | Missing >2 days per cycle due to pain | Meets threshold for secondary dysmenorrhea workup | | Pain not relieved by standard NSAID dosing | Consider empirical hormonal therapy or laparoscopy | | CA-125 >35 U/mL with pelvic pain | Low specificity but supports further imaging | | Endometrioma >3 cm on ultrasound | Typically managed surgically, especially before IVF |

Data thresholds drawn from ACOG Practice Bulletin No. 114 and ASRM practice guidelines.